Anika Therapeutics (ANIK) Set to Announce Earnings on Wednesday

Anika Therapeutics (NASDAQ:ANIK) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Anika Therapeutics has set its FY 2024 guidance at EPS.Parties that are interested in participating in the company’s conference call can do so using this link.

Anika Therapeutics (NASDAQ:ANIK) last released its earnings results on Wednesday, March 13th. The biotechnology company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.20. Anika Therapeutics had a negative net margin of 49.60% and a negative return on equity of 2.10%. The company had revenue of $42.97 million for the quarter, compared to analysts’ expectations of $41.51 million. On average, analysts expect Anika Therapeutics to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Anika Therapeutics Stock Performance

NASDAQ ANIK opened at $27.59 on Monday. Anika Therapeutics has a 12 month low of $16.54 and a 12 month high of $28.19. The stock has a market cap of $409.16 million, a price-to-earnings ratio of -4.88, a PEG ratio of 2.46 and a beta of 0.74. The company’s 50 day moving average is $25.65 and its two-hundred day moving average is $23.38.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. StockNews.com upgraded shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, March 14th. Stephens restated an “equal weight” rating and set a $22.00 target price on shares of Anika Therapeutics in a research note on Thursday, March 14th. Finally, Barrington Research lifted their price objective on shares of Anika Therapeutics from $29.00 to $37.00 and gave the company an “outperform” rating in a research report on Thursday, March 14th.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.